Cargando…

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma

BACKGROUND: The potential benefits and possible risks associated with combined nimotuzumab and concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma (NPC) have yet to be determined. METHODS: The databases PubMed, Web of Science, China National Knowledge Infrastructure, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhanzhan, Li, Yanyan, Yan, Shipeng, Fu, Jun, Zhou, Qin, Huang, Xinqiong, Shen, Liangfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694200/ https://www.ncbi.nlm.nih.gov/pubmed/29180878 http://dx.doi.org/10.2147/OTT.S141538

Ejemplares similares

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
por: Song, Xinmao, et al.
Publicado: (2019)

Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
por: Liu, Zhi-gang, et al.
Publicado: (2016)

Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Wang, Lili, et al.
Publicado: (2023)

Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2017)

Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
por: Yao, Ji-Jin, et al.
Publicado: (2018)

Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study
por: Zhang, Shuai, et al.
Publicado: (2018)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yang, Zhi, et al.
Publicado: (2023)

Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study
por: Jiang, Danxian, et al.
Publicado: (2023)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Mean cerebral blood volume is an effective diagnostic index of recurrent and radiation injury in glioma patients: A meta-analysis of diagnostic test
por: Li, Zhanzhan, et al.
Publicado: (2017)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China
por: Tian, Xin, et al.
Publicado: (2020)

Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: A meta-analysis
por: Li, Zhanzhan, et al.
Publicado: (2016)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yin, Yuanxiu, et al.
Publicado: (2022)

Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis
por: Liang, Zhong Guo, et al.
Publicado: (2018)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021)

Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
por: Huang, Jianfeng, et al.
Publicado: (2017)

MAP2K6 is associated with radiation resistance and adverse prognosis for locally advanced nasopharyngeal carcinoma patients
por: Li, Zhanzhan, et al.
Publicado: (2018)

Paranasal Sinus Invasion Should Be Classified as T4 Disease in Advanced Nasopharyngeal Carcinoma Patients Receiving Radiotherapy
por: Zhao, Yajie, et al.
Publicado: (2020)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes
por: Zang, Jian, et al.
Publicado: (2018)

Quantitative Tyrosine Phosphoproteomic Analysis of Resistance to Radiotherapy in Nasopharyngeal Carcinoma Cells
por: Shen, Lin, et al.
Publicado: (2020)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: An update evidence from 44 studies
por: Li, Zhanzhan, et al.
Publicado: (2018)

Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer
por: Zhang, Lei, et al.
Publicado: (2022)

Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy
por: Zhang, Guangying, et al.
Publicado: (2019)

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
por: Li, H. M., et al.
Publicado: (2016)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma
por: Liang, Zhong-Guo, et al.
Publicado: (2017)

Quantitative Proteomic Analysis Identifies MAPK15 as a Potential Regulator of Radioresistance in Nasopharyngeal Carcinoma Cells
por: Li, Zhanzhan, et al.
Publicado: (2018)

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
por: Huang, Jianfeng, et al.
Publicado: (2018)

Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial
por: Huang, Jian-feng, et al.
Publicado: (2016)

Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer
por: Chen, Yong-Fa, et al.
Publicado: (2017)

Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience
por: Rawat, Shyamji, et al.
Publicado: (2019)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
por: Setakornnukul, Jiraporn, et al.
Publicado: (2018)

Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis
por: Zhang, Lijuan, et al.
Publicado: (2015)

Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?
por: Yao, Ji-Jin, et al.
Publicado: (2019)

Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
por: Chen, Wenli, et al.
Publicado: (2019)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2v1c8m4s7ommkjffh7jv9mls4a